Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase III study of Hydroxyprogesterone caproate (LPCN-1107) in reducing the risk of preterm birth (PTB) in women with singleton pregnancy who have a history of singleton spontaneous PTB.

Next Previous
Trial Profile

A pivotal phase III study of Hydroxyprogesterone caproate (LPCN-1107) in reducing the risk of preterm birth (PTB) in women with singleton pregnancy who have a history of singleton spontaneous PTB.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyprogesterone (Primary) ; Hydroxyprogesterone
  • Indications Preterm birth
  • Focus Registrational; Therapeutic Use
  • Sponsors Lipocine

    • Most Recent Events

    • 26 Jun 2017 According to a company media release, Lipocine has submitted a Special Protocol Assessment ("SPA") request to the U.S. Food and Drug Administration as part of the ongoing interaction with the FDA on the detailed design of the planned Phase 3 clinical development program for LPCN 1107 for prevention of recurrent preterm birth ("PTB") with history of singleton pregnancy.
    • 11 Mar 2017 New trial record
    • 06 Mar 2017 According to a Lipocine media release, the company plans to submit the LPCN-1107 Phase 3 protocol to the FDA via a Special Protocol Assessment (SPA) in the first half of 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top